

Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/MA0E2C08A781EN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: MA0E2C08A781EN

Abstracts

The 7 major menorrhagia markets reached a value of US\$ 970 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1,380 Million by 2034, exhibiting a growth rate (CAGR) of 3.26% during 2024-2034.

The menorrhagia market has been comprehensively analyzed in IMARC's new report titled "Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Menorrhagia is a medical term used to describe prolonged or abnormally heavy menstrual bleeding in women. It refers to menstrual periods that involve excessive blood loss, typically exceeding 80 milliliters or lasting longer than seven days. This condition can be distressing and may interfere with a woman's daily activities and quality of life. The common symptoms associated with the ailment include abdominal pain, passing blood clots that are the size of a quarter or bigger, fatigue, weakness, shortness of breath, pale skin, intense cramping, etc. To diagnose menorrhagia, a healthcare provider may review the woman's medical history, conduct a physical examination, and suggest additional tests, such as blood workups, to check for anemia or hormonal imbalances. A transvaginal ultrasound, which involves inserting a probe into the vagina to obtain pictures of the uterus and ovaries to help in identifying structural abnormalities, is also utilized among patients. The doctor may further recommend several diagnostic procedures, including magnetic resonance imaging, hysteroscopy, endometrial biopsy, etc., to rule out other possible causes and validate a diagnosis.

The rising incidences of hormonal imbalances, particularly between estrogen and progesterone, that can disrupt the normal menstrual cycle and lead to heavy bleeding are primarily driving the menorrhagia market. In addition to this, the increasing

prevalence of various associated risk factors, such as the use of intrauterine devices, blood clotting disorders, endometrial polyps, etc., is also bolstering the market growth. Furthermore, the widespread adoption of nonsteroidal anti-inflammatory drugs, including ibuprofen and naproxen sodium, to reduce menstrual bleeding and alleviate pain is acting as another significant growth-inducing factor. Apart from this, the escalating application of minimally invasive endometrial ablation therapy for women who prefer non-hormonal treatment, owing to its numerous advantages, such as rapid recovery time, cost-effectiveness, and improved quality of life, is also creating a positive outlook for the market. Additionally, the emerging popularity of uterine artery embolization techniques for treating this disease condition, since they block the blood flow to the uterus by injecting tiny particles into the uterine arteries, leading to symptom relief, is expected to drive the menorrhagia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the menorrhagia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for menorrhagia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the menorrhagia market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the menorrhagia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the menorrhagia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current menorrhagia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the menorrhagia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the menorrhagia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the menorrhagia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of menorrhagia across the seven major markets?

What is the number of prevalent cases (2018-2034) of menorrhagia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of menorrhagia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with menorrhagia across the seven major markets?

What is the size of the menorrhagia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of menorrhagia?

What will be the growth rate of patients across the seven major markets?

Menorrhagia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for menorrhagia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the menorrhagia market?

What are the key regulatory events related to the menorrhagia market?

What is the structure of clinical trial landscape by status related to the menorrhagia market?

What is the structure of clinical trial landscape by phase related to the menorrhagia market?

What is the structure of clinical trial landscape by route of administration related to the menorrhagia market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MENORRHAGIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 MENORRHAGIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 MENORRHAGIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2018-2023)

7.2.2 Epidemiology Forecast (2024-2034)

7.2.3 Epidemiology by Age (?2018-2034?)

7.2.4 Epidemiology by Gender (?2018-2034?)

7.2.5 Diagnosed Cases (?2018-2034?)

7.2.6 Patient Pool/Treated Cases (?2018-2034?)

7.3 Epidemiology Scenario - United States

7.3.1 Epidemiology Scenario (2018-2023)

7.3.2 Epidemiology Forecast (2024-2034)

7.3.3 Epidemiology by Age (?2018-2034?)

7.3.4 Epidemiology by Gender (?2018-2034?)

7.3.5 Diagnosed Cases (?2018-2034?)

7.3.6 Patient Pool/Treated Cases (?2018-2034?)

7.4 Epidemiology Scenario - Germany

7.4.1 Epidemiology Scenario (2018-2023)

7.4.2 Epidemiology Forecast (2024-2034)

7.4.3 Epidemiology by Age (?2018-2034?)

7.4.4 Epidemiology by Gender (?2018-2034?)

7.4.5 Diagnosed Cases (?2018-2034?)

7.4.6 Patient Pool/Treated Cases (?2018-2034?)

7.5 Epidemiology Scenario - France

7.5.1 Epidemiology Scenario (2018-2023)

7.5.2 Epidemiology Forecast (2024-2034)

7.5.3 Epidemiology by Age (?2018-2034?)

7.5.4 Epidemiology by Gender (?2018-2034?)

7.5.5 Diagnosed Cases (?2018-2034?)

7.5.6 Patient Pool/Treated Cases (?2018-2034?)

7.6 Epidemiology Scenario - United Kingdom

7.6.1 Epidemiology Scenario (2018-2023)

7.6.2 Epidemiology Forecast (2024-2034)

7.6.3 Epidemiology by Age (?2018-2034?)

7.6.4 Epidemiology by Gender (?2018-2034?)

7.6.5 Diagnosed Cases (?2018-2034?)

7.6.6 Patient Pool/Treated Cases (?2018-2034?)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 MENORRHAGIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 MENORRHAGIA - UNMET NEEDS

10 MENORRHAGIA - KEY ENDPOINTS OF TREATMENT

11 MENORRHAGIA - MARKETED PRODUCTS

- 11.1 List of Menorrhagia Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Lysteda (Tranexamic acid controlled release) - Amring Pharmaceuticals
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 MENORRHAGIA - PIPELINE DRUGS

12.1 List of Menorrhagia Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. MENORRHAGIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. MENORRHAGIA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 MENORRHAGIA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Menorrhagia - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Menorrhagia - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Menorrhagia - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Menorrhagia - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

- 15.3.3 Menorrhagia - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Menorrhagia - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Menorrhagia - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Menorrhagia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Menorrhagia - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Menorrhagia - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Menorrhagia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Menorrhagia - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Menorrhagia - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Menorrhagia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Menorrhagia - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Menorrhagia - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Menorrhagia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Menorrhagia - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Menorrhagia - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Menorrhagia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Menorrhagia - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Menorrhagia - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Menorrhagia - Access and Reimbursement Overview

16 MENORRHAGIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 MENORRHAGIA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 MENORRHAGIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/MA0E2C08A781EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MA0E2C08A781EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

